Literature DB >> 19867971

ANTIBLASTIC IMMUNITY.

A R Dochez1, O T Avery.   

Abstract

1. Antipneumococcus serum possesses the power of inhibiting for a certain period of time the multiplication of pneumococci. 2. It also has the capacity of inhibiting the proteolytic and glycolytc functions of pneumococci. 3. This power is acquired for the first time or appears in increased amounts in human serum at the time of crisis in lobar pneumonia. 4. The retardation of bacterial growth is thought to be dependent upon the inhibition of metabolic function due to the presence of anti-enzymotic substances in antipneumococcus serum. To this phenomenon we have applied the term antiblastic immunity.

Entities:  

Year:  1916        PMID: 19867971      PMCID: PMC2125341          DOI: 10.1084/jem.23.1.61

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  4 in total

1.  GROWTH-INHIBITORY SUBSTANCES IN PNEUMOCOCCUS CULTURES.

Authors:  H J Morgan; O T Avery
Journal:  J Exp Med       Date:  1924-02-29       Impact factor: 14.307

2.  STUDIES ON ANTIBLASTIC IMMUNITY.

Authors:  F G Blake
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

3.  IMMUNITY FACTORS IN PNEUMOCOCCUS INFECTION IN THE DOG.

Authors:  C G Bull
Journal:  J Exp Med       Date:  1916-07-01       Impact factor: 14.307

4.  A STUDY BY THE SINGLE CELL METHOD OF THE INFLUENCE OF HOMOLOGOUS ANTIPNEUMOCOCCIC SERUM ON THE GROWTH RATE OF PNEUMOCOCCUS.

Authors:  M A Barber
Journal:  J Exp Med       Date:  1919-11-30       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.